Moderna Inc (MRNA)

[axelvento]

"it's written on the wall"The big news in Moderna's Q4 update was a surprise profit of $217 million, or $0.53 per share, based on generally accepted accounting principles (GAAP). The average analysts' estimate was for a Q4 loss of $0.90 per share.

Moderna also reported Q4 revenue of $2.8 billion, down from $5.1 billion in the prior-year period. However, this result was well above the consensus revenue estimate of $2.3 billion.

I don't think Moderna stock is a buy solely because of its Q4 results. My view is that risk-averse investors will be better off going with other stocks.

However, aggressive investors could find Moderna appealing right now. The company hopes to win U.S. regulatory approval for its respiratory syncytial virus (RSV) vaccine soon. It's also optimistic about filing for approval of seasonal flu vaccine mRNA-1010 this year. I predict Moderna's future will be brighter than its recent past.

https://www.fool.com/investing/2024/02/22/why-moderna-stock-is-jumping-today/